中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 10
Oct.  2023
Turn off MathJax
Article Contents

Recompensation of liver cirrhosis: Current status and challenges

DOI: 10.3969/j.issn.1001-5256.2023.10.027
Research funding:

‍2020 Shaanxi Provincial Department of Education project (20JK0343);

Key Scientific Research Project of Inheritance and Innovation of Traditional Chinese Medicine and Development of “Qin Medicine” by Shaanxi Provincial Administration of Traditional Chinese Medicine ;

Research Projects of Xi’an Medical College at University Level in 2021 (2021QN20)

More Information
  • Corresponding author: LI Xueping,lxp86@163.com (ORCID: 0000-0002-0556-9728); MI Man,853002274@qq.com (ORCID: 0000-0001-7408-5113)
  • Received Date: 2023-03-24
  • Published Date: 2023-10-30
  • ‍Traditionally, the progression from compensated liver cirrhosis to decompensated liver cirrhosis has been considered an irreversible point in the natural history of the disease; however, with the suppression of underlying etiology, cure, and disease regression, this view is challenged by an increasing number of new evidence, and the idea of “recompensation of liver cirrhosis” is gradually being accepted. In recent years, scholars in China and globally have been exploring the specific definition of recompensation of liver cirrhosis and the clinical features of patients. By summarizing the recent studies on recompensation of liver cirrhosis in China and globally, integrating existing views, and analyzing related research evidence, this article points out the main challenges in the field of recompensation at this stage, including the lack of in-depth clinical and basic research, the need to define recompensation in the context of NAFLD, and related ethical issues, in order to provide new directions for future research in this field.

     

  • loading
  • [1]
    GRACIA-SANCHO J, MARRONE G, FERNÁNDEZ-IGLESIAS A. Hepatic microcirculation and mechanisms of portal hypertension[J]. Nat Rev Gastroenterol Hepatol, 2019, 16( 4): 221- 234. DOI: 10.1038/s41575-018-0097-3.
    [2]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol, 2018, 69( 2): 406- 460. DOI: 10.1016/j.jhep.2018.03.024.
    [3]
    XU XY, DING HG, LI WG, et al. Chinese guidelines on the management of liver cirrhosis(abbreviated version)[J]. World J Gastroenterol, 2020, 26( 45): 7088- 7103. DOI: 10.3748/wjg.v26.i45.7088.
    [4]
    EL-SHERIF O, JIANG ZG, TAPPER EB, et al. Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection[J]. Gastroenterology, 2018, 154( 8): 2111- 2121.e 8. DOI: 10.1053/j.gastro.2018.03.022.
    [5]
    TSOCHATZIS EA, BOSCH J, BURROUGHS AK. Liver cirrhosis[J]. Lancet, 2014, 383( 9930): 1749- 1761. DOI: 10.1016/S0140-6736(14)60121-5.
    [6]
    DE FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76( 4): 959- 974. DOI: 10.1016/j.jhep.2021.12.022.
    [7]
    SHARMA S, ROY A. Recompensation in cirrhosis: current evidence and future directions[J]. J Clin Exp Hepatol, 2023, 13( 2): 329- 334. DOI: 10.1016/j.jceh.2022.08.002.
    [8]
    ARAVINTHAN AD, BARBAS AS, DOYLE AC, et al. Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study[J]. Transpl Int, 2017, 30( 11): 1140- 1149. DOI: 10.1111/tri.13008.
    [9]
    MACKEN L, GELSON W, PRIEST M, et al. Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort[J]. J Med Virol, 2019, 91( 11): 1979- 1988. DOI: 10.1002/jmv.25552.
    [10]
    SHEIKH NT, SHAUKAT MT, HUSSAIN A, et al. SVR achievement in triple therapy treated hepatitis C induced cirrhosis: A dual center retrospective cohort study[J]. Ann Med Surg(Lond), 2022, 80: 104193. DOI: 10.1016/j.amsu.2022.104193.
    [11]
    POSE E, TORRENTS A, REVERTER E, et al. A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement[J]. J Hepatol, 2021, 75( 2): 275- 283. DOI: 10.1016/j.jhep.2021.02.033.
    [12]
    GENTILE I, SCOTTO R, COPPOLA C, et al. Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort(Liver Network Activity-LINA cohort)[J]. Hepatol Int, 2019, 13( 1): 66- 74. DOI: 10.1007/s12072-018-9914-6.
    [13]
    JANG JW, CHOI JY, KIM YS, et al. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis[J]. Hepatology, 2015, 61( 6): 1809- 1820. DOI: 10.1002/hep.27723.
    [14]
    RAO HY, WU N. Effect of nucleoside(acid) analogues on liver fibrosis in chronic hepatitis B[J]. Beijing Med, 2014, 36( 6): 421- 423. DOI: 10.15932/j.0253-9713.2014.06.013.

    饶慧瑛, 武楠. 核苷(酸)类似物长期治疗对慢性乙型肝炎肝纤维化的影响[J]. 北京医学, 2014, 36( 6): 421- 423. DOI: 10.15932/j.0253-9713.2014.06.013.
    [15]
    NIKOLAIDIS N, VASSILIADIS T, GIOULEME O, et al. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B[J]. Clin Transplant, 2005, 19( 3): 321- 326. DOI: 10.1111/j.1399-0012.2005.00340.x.
    [16]
    SHIM JH, LEE HC, KIM KM, et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis[J]. J Hepatol, 2010, 52( 2): 176- 182. DOI: 10.1016/j.jhep.2009.11.007.
    [17]
    XU X, WANG H, ZHAO W, et al. Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case-control study[J]. BMJ Open, 2021, 11( 6): e043083. DOI: 10.1136/bmjopen-2020-043083.
    [18]
    VILLANUEVA C, ALBILLOS A, GENESCÀ J, et al. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension[J]. Hepatology, 2016, 63( 1): 197- 206. DOI: 10.1002/hep.28264.
    [19]
    COSTA D, SIMBRUNNER B, JACHS M, et al. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality[J]. J Hepatol, 2021, 74( 4): 819- 828. DOI: 10.1016/j.jhep.2020.10.004.
    [20]
    VILLANUEVA C, ALBILLOS A, GENESCÀ J, et al. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis[J]. J Hepatol, 2021, 75( 3): 589- 599. DOI: 10.1016/j.jhep.2021.04.022.
    [21]
    BEDOSSA P. Reversibility of hepatitis B virus cirrhosis after therapy: who and why[J]. Liver Int, 2015, 35 Suppl 1: 78- 81. DOI: 10.1111/liv.12710.
    [22]
    MØLLER S, BENDTSEN F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis[J]. Liver Int, 2018, 38( 4): 570- 580. DOI: 10.1111/liv.13589.
    [23]
    TREBICKA J, AMOROS A, PITARCH C, et al. Addressing profiles of systemic inflammation across the different clinical phenotypes of acutely decompensated cirrhosis[J]. Front Immunol, 2019, 10: 476. DOI: 10.3389/fimmu.2019.00476.
    [24]
    WANG Q, ZHAO H, DENG Y, et al. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis[J]. J Hepatol, 2022, 77( 6): 1564- 1572. DOI: 10.1016/j.jhep.2022.07.037.
    [25]
    NABATCHIKOVA EA, ABDURAKHMANOV DT, ROZINA TP, et al. Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: A long-term single-center experience[J]. Clin Res Hepatol Gastroenterol, 2021, 45( 6): 101714. DOI: 10.1016/j.clinre.2021.101714.
    [26]
    IWAKIRI Y, TREBICKA J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy[J]. JHEP Rep, 2021, 3( 4): 100316. DOI: 10.1016/j.jhepr.2021.100316.
    [27]
    SAAB S. Portal hypertension[J]. Clin Liver Dis, 2019, 23( 4):-. DOI: 10.1016/j.cld.2019.08.001.
    [28]
    VILLANUEVA C, ALBILLOS A, GENESCÀ J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension(PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial[J]. Lancet, 2019, 393( 10181): 1597- 1608. DOI: 10.1016/S0140-6736(18)31875-0.
    [29]
    MONTEIRO S, GRANDT J, USCHNER FE, et al. Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation[J]. Gut, 2021, 70( 2): 379- 387. DOI: 10.1136/gutjnl-2019-320170.
    [30]
    YANG L, KWON J, POPOV Y, et al. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice[J]. Gastroenterology, 2014, 146( 5): 1339- 1350.e 1. DOI: 10.1053/j.gastro.2014.01.061.
    [31]
    SALEHI S, TAVABIE OD, VERMA S, et al. Serum microrna signatures in recovery from acute and chronic liver injury and selection for liver transplantation[J]. Liver Transpl, 2020, 26( 6): 811- 822. DOI: 10.1002/lt.25781.
    [32]
    REIBERGER T, HOFER BS. The Baveno VII concept of cirrhosis recompensation[J]. Dig Liver Dis, 2023, 55( 4): 431- 441. DOI: 10.1016/j.dld.2022.12.014.
    [33]
    MÉNDEZ-SÁNCHEZ N, PAL SC. New terms for fatty liver disease other than MAFLD: Time for a reality check[J]. J Hepatol, 2022, 77( 6): 1716- 1717. DOI: 10.1016/j.jhep.2022.08.009.
    [34]
    ASRANI SK, DEVARBHAVI H, EATON J, et al. Burden of liver diseases in the world[J]. J Hepatol, 2019, 70( 1): 151- 171. DOI: 10.1016/j.jhep.2018.09.014.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (264) PDF downloads(92) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return